333 related articles for article (PubMed ID: 33908862)
1. [Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance].
Bouabdallah S; Mariko ML; Besson J; Dellis O
Med Sci (Paris); 2021 Apr; 37(4):406-408. PubMed ID: 33908862
[No Abstract] [Full Text] [Related]
2. L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.
Zhang JY; Zhang PP; Zhou WP; Yu JY; Yao ZH; Chu JF; Yao SN; Wang C; Lone W; Xia QX; Ma J; Yang SJ; Liu KD; Dong ZG; Guo YJ; Smith LM; McKeithan TW; Chan WC; Iqbal J; Liu YY
Clin Cancer Res; 2019 Jul; 25(13):4168-4178. PubMed ID: 30824586
[TBL] [Abstract][Full Text] [Related]
3. The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.
Liu Y; Gu JJ; Yang L; Tsai PC; Guo Y; Xue K; Xia Z; Liu X; Lv F; Cao J; Hong X; Mavis C; Hernandez-Ilizaliturri FJ; Zhang Q
Aging (Albany NY); 2020 Dec; 13(1):181-193. PubMed ID: 33288735
[TBL] [Abstract][Full Text] [Related]
4. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
5. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
6. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
Shimazu Y; Nohgawa M
J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
[No Abstract] [Full Text] [Related]
7. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
8. Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
Lunning MA; Armitage JO
Haematologica; 2015 Jul; 100(7):853-5. PubMed ID: 26130511
[No Abstract] [Full Text] [Related]
9. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.
Shi Y; Song Y; Qin Y; Zhang Q; Han X; Hong X; Wang D; Li W; Zhang Y; Feng J; Yang J; Zhang H; Jin C; Yang Y; Hu J; Wang Z; Jin Z; Su H; Wang H; Yang H; Fu W; Zhang M; Zhang X; Chen Y; Ke X; Liu L; Yu D; Chen G; Wang X; Jin J; Sun T; Du X; Cheng Y; Yi P; Zhao X; Ma C; Cheng J; Chai K; Luk A; Liu E; Zhang X
J Hematol Oncol; 2020 Apr; 13(1):38. PubMed ID: 32299513
[TBL] [Abstract][Full Text] [Related]
10. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
11. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
12. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
13. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
14. Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
Lim KJC; Filshie R
Lancet Haematol; 2023 Dec; 10(12):e942-e943. PubMed ID: 37922924
[No Abstract] [Full Text] [Related]
15. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
[No Abstract] [Full Text] [Related]
16. Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era.
Liang X; Hu R; Li Q; Wang C; Liu Y
Exp Hematol; 2023 Jun; 122():1-9. PubMed ID: 36933759
[No Abstract] [Full Text] [Related]
17. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
18. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.
Delage L; Manzoni D; Quinquenet C; Fontaine J; Maarek A; Chabane K; Mosnier I; Hayette S; Callet-Bauchu E; Grange B; Plesa A; Sujobert P
Haematologica; 2019 Mar; 104(3):e114-e116. PubMed ID: 30545922
[No Abstract] [Full Text] [Related]
20. Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma.
Lee S; Fujita K; Negoro E; Morishita T; Oiwa K; Tsukasaki H; Kinoshita K; Kawai Y; Ueda T; Yamauchi T
Haematologica; 2020 Aug; 105(8):e415-e418. PubMed ID: 31919079
[No Abstract] [Full Text] [Related]
[Next] [New Search]
